⊛
QBR / EBR builder
Customer successTurns a quarter of usage telemetry, support history, and milestone data into a structured, exec-ready Quarterly/Executive Business Review — value delivered, risks, a health narrative, and a forward roadmap with expansion asks — ready to drop into slides.
The routing recipe
Job typeComplex reasoningPolicyBest qualityConstraintsctx ≥ 128k
routes to
NVIDIA Nemotron 3 Ultra 550B-A55B nvidia
nvidia:nvidia/nemotron-3-ultra-550b-a55b
93.7
match score
96.5
task fit
100
cost
59.5
speed
Why this model from benchmarks & capabilities
- "Complex reasoning" leans hardest on reasoning; NVIDIA Nemotron 3 Ultra 550B-A55B scores 100/100 there — top-1 of 54 chat models.
- Strength on this class of work shows up on GPQA Diamond, MMLU-Pro, BIG-Bench Hard, where NVIDIA models are competitive.
- Cost: runs on NVIDIA free credits / self-hostable NIM — effectively $0 marginal. Speed: ~70 tok/s (estimated).
- Chosen over DeepSeek V4 Pro for cheaper & faster.
| Capability the job needs | Weight | NVIDIA Nemotron 3 Ultra 550B-A55B | Catalog rank |
|---|---|---|---|
| reasoning | 1.00 | #1 of 54 | |
| math | 0.60 | #2 of 54 | |
| knowledge | 0.50 | #3 of 54 |
Relevant benchmarksGPQA Diamond MMLU-Pro BIG-Bench Hard LiveBench (reasoning)
EconomicsCost: runs on NVIDIA free credits / self-hostable NIM — effectively $0 marginal.
Speed: ~70 tok/s (estimated). vs runner-upChosen over DeepSeek V4 Pro for cheaper & faster. (DeepSeek V4 Pro, score 91.8)
Speed: ~70 tok/s (estimated). vs runner-upChosen over DeepSeek V4 Pro for cheaper & faster. (DeepSeek V4 Pro, score 91.8)
Example result
Sample input ▾
Customer: Lattice Health (HIPAA + SOC 2 Type II), Enterprise tier, EBR for Q2. Telemetry: 142 controls monitored (was 96 last Q); automated evidence collection at 88% (was 61%); 9 active integrations; access reviews run monthly (was ad-hoc); 31 active users (24 last Q). Audit: SOC 2 Type II renewed with zero exceptions in May; HIPAA risk assessment completed in-product. Tickets: 14 total, median first-response 3h, 1 escalation (SSO outage, resolved 6h). Trust Center: served 47 security questionnaires auto-answered (est. ~4h each saved). Calls: VP Eng (sponsor) said "this paid for itself when we closed the Memorial Hospital deal — their security review took 3 days instead of 6 weeks." Champion (Sec lead) asked about FedRAMP and pen-test management. Renewal in 5 months.
EXECUTIVE BUSINESS REVIEW — Lattice Health · Q2
1) Executive summary
• Win: SOC 2 Type II renewed with ZERO exceptions and HIPAA risk assessment closed in-product — clean audit, no fire drill.
• Risk: Renewal is in 5 months and depends on one sponsor (VP Eng) + one champion (Sec lead); no third stakeholder yet.
• Ask: 30-min exec session to scope FedRAMP path and lock a multi-year renewal ahead of the cycle.
2) Value delivered
• Audit-readiness: 142 controls monitored (+48% QoQ); automated evidence 88% (up from 61%) — evidence is now collected, not chased.
• Hours saved: 47 questionnaires auto-answered via Trust Center × ~4h ≈ 188 sec-eng hours saved this quarter (~$23k at a loaded $120/hr; assumption stated).
• Revenue unblocked: Memorial Hospital security review cleared in 3 days vs. their usual 6 weeks (sponsor quote) — a deal the customer attributes directly to iCompaas.
• Operational maturity: access reviews moved from ad-hoc → monthly; SOC 2 renewed with zero exceptions.
3) Health narrative
Healthy and expanding. Adoption is up across every axis — controls +48%, evidence automation +27pts, users 24→31 — and the product is now load-bearing in their sales motion (security reviews), which is the stickiest possible position. Sentiment is strong: the VP Eng publicly credited a closed deal to the platform. The one structural fragility is concentration on two people; broadening the footprint into the GRC/legal org is the retention play.
4) Risks & watch-items
• Stakeholder concentration (Med) → introduce a third user in GRC/legal at the EBR; owner: CSM.
• SSO outage left an impression (Low, resolved 6h) → send the RCA proactively; owner: Support.
• Renewal in 5 months with no commercial conversation yet (Med) → open renewal + expansion as one motion now; owner: CSM + AE.
5) Next-quarter roadmap
• Scope FedRAMP readiness gap-assessment — us — Jul 31.
• Onboard pen-test management module + import latest VAPT report — them, we coach — Aug 15.
• Add 1 GRC/legal stakeholder + Trust Center exec view — us — Aug 30.
• Pre-stage multi-year renewal proposal — AE — Sep 15.
6) Expansion opportunities
• FedRAMP module — champion explicitly asked; opens public-sector pipeline (business reason: unblocks gov/health-adjacent deals).
• Pen-test / VAPT management — they run pentests but track them outside iCompaas; consolidating closes an evidence gap auditors flag.
• Vendor-risk tier upgrade — 9 integrations and growing; current tier under-covers subprocessor monitoring.
(Inferred vs. measured: $/hr cost and the 188-hr figure are modeled from the 47×4h input; all other numbers are measured telemetry.)
Test it on your own data